Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Filings indexed 2,855 across all filing types
Latest filing 2025-11-06 Interim / Quarterly Rep…
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first nine months of 2025, detailing financial performance, balance sheet data, and business updates. It contains substantive financial tables and analysis, which distinguishes it from a simple earnings release or a report publication announcement. It fits the definition of an Interim/Quarterly Report (IR). 9M 2025
2025-11-06 Dutch
6-K Filing
Regulatory Filings
2025-11-06 English
Galapagos Reports Nine Months 2025 Financial Results and Provides Business Update .pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report covering the first nine months of 2025 for Galapagos NV. It includes detailed financial statements (consolidated key figures), management's analysis of the results, business updates, and operational highlights. Since it covers a period shorter than a full fiscal year and contains substantive financial data and analysis, it is classified as an Interim/Quarterly Report (IR). 9M 2025
2025-11-05 English
Galapagos rapporteert financiële resultaten over de eerste negen maanden van 2025 en geeft bedrijfsupdate.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the first nine months of 2025, detailing financial performance, balance sheet data, and business updates. It contains substantive financial tables and analysis, which distinguishes it from a simple earnings release or a report publication announcement. It fits the definition of an Interim/Quarterly Report (IR). 9M 2025
2025-11-05 Dutch
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV announcing that they will present new clinical data regarding their CAR-T cell therapy candidate (GLPG5101) at the upcoming American Society of Hematology (ASH) conference. It provides details on the study, the abstracts to be presented, and the company's strategic outlook. This type of announcement, which provides updates on clinical trial progress and upcoming scientific presentations, is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement regarding company activities and research updates.
2025-11-04 Dutch
Galapagos to Present New Data from Cell Therapy Program at ASH 2025
Regulatory Filings Classification · 95% confidence The document is a press release from Galapagos NV announcing the presentation of new clinical data for their CAR-T cell therapy candidate (GLPG5101) at the upcoming American Society of Hematology (ASH) Annual Meeting. It details the study abstracts, presentation schedules, and provides background on the clinical program. It does not constitute a formal financial report, proxy statement, or regulatory filing, but rather a corporate announcement regarding scientific/clinical progress, which falls under the general regulatory announcement category.
2025-11-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.